10-Q: AirSculpt Technologies Reports First Quarter 2024 Results, Revenue Up 3.9%

AirSculpt Technologies reported a 3.9% increase in revenue for the first quarter of 2024, driven by new center openings, while also seeing a significant reversal of stock compensation expense.

Summary

• AirSculpt Technologies reported a revenue of $47.6 million for the first quarter of 2024, a 3.9% increase compared to $45.8 million in the same period of 2023.
• The company performed 3,746 cases in Q1 2024, up from 3,640 cases in Q1 2023.
• Net income for the quarter was $6.0 million, a significant improvement from a net loss of $0.014 million in the first quarter of 2023.
• The company experienced a $10.4 million cumulative reversal of stock compensation expense due to reassessing the probability of achieving a revenue performance target.
• Adjusted EBITDA for the quarter was $7.3 million, compared to $9.5 million in the same period last year.
• The company's same-center revenue declined by 10.2%, which is attributed to weaker performance in the broader aesthetic and consumer retail industries.
• The company had 27 centers and 57 procedure rooms as of March 31, 2024, compared to 23 centers and 49 procedure rooms as of March 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive revenue growth and a return to profitability, but also highlights concerns about same-center revenue decline and increased customer acquisition costs. The reversal of stock compensation expense is a one-off event and does not indicate underlying business strength.

Positives

• The company achieved a net income of $6.0 million, a significant improvement from a net loss in the same quarter of the previous year.
• The company's revenue increased by 3.9% year-over-year.
• The company's case volume increased to 3,746 in Q1 2024 from 3,640 in Q1 2023.
• The company expanded its footprint to 27 centers and 57 procedure rooms as of March 31, 2024.
• The company experienced a $10.4 million cumulative reversal of stock compensation expense.

Negatives

• Same-center revenue declined by 10.2% year-over-year.
• Adjusted EBITDA decreased to $7.3 million from $9.5 million in the same period last year.
• Customer acquisition costs increased to approximately $2,990 per customer in Q1 2024 from $2,360 in Q1 2023.
• The company's working capital was $(6.8) million at March 31, 2024, compared to $(4.4) million at December 31, 2023.

Risks

• The company faces increased competition in the weight loss and obesity solutions market, including the impact of new weight-loss drugs.
• The company's future results could be affected by the inability to open new centers due to rising interest rates and increased operating expenses due to rising inflation.
• The company is subject to litigation and medical malpractice claims.
• The company's same-store revenue decline is primarily attributed to weaker than expected performance across the broader aesthetic and consumer retail industries, particularly related to customers that are more price sensitive.

Future Outlook

The company expects its marketing and corporate support costs to continue to increase as it opens new centers and expands support to existing centers. The company believes that cash from operations and the revolving credit facility will be sufficient for working capital, capital expenditures, and debt payments for at least the next 12 months.

Management Comments

• Management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, which are non-GAAP financial measures.
• Management considers Adjusted EBITDA and Adjusted Net Income each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis.

Industry Context

The company's performance is being impacted by broader trends in the aesthetic and consumer retail industries, particularly with price-sensitive customers. The company also faces increased competition in the weight loss and obesity solutions market, including the impact of new weight-loss drugs.

Comparison to Industry Standards

• The company's same-center revenue decline of 10.2% indicates a potential underperformance compared to industry averages, as many aesthetic and medical service providers are experiencing growth.
• The increase in customer acquisition costs to $2,990 per customer suggests a need to evaluate marketing strategies for efficiency compared to competitors.
• The company's adjusted EBITDA margin of 15.4% is lower than the 20.6% reported in the same period last year, indicating a need to improve operational efficiency or pricing strategies.
• The company's expansion to 27 centers and 57 procedure rooms is a positive sign of growth, but the same-center revenue decline suggests that the company needs to focus on driving growth in existing locations.

Legal Proceedings

• The company is involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the PAs employed and affiliated physicians.
• The company believes that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, and cash flows.

Stakeholder Impact

• Shareholders will be impacted by the increase in net income, but also by the decline in same-center revenue and the increase in customer acquisition costs.
• Employees may be impacted by the company's expansion plans and the need to support new centers.
• Customers may be impacted by the company's marketing efforts and the availability of new centers.

Next Steps

• The company intends to continue investing in sales and marketing capabilities as it adds new centers and further increases brand awareness.
• The company plans to continue expanding its corporate team to support the opening of new centers and growth at existing facilities.
• The company will perform its annual review of goodwill impairment in October 2024.

Key Dates

Keywords

AirSculpt, liposuction, body contouring, revenue, EBITDA, net income, stock compensation, medical procedures, aesthetic market, de novo centers